Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.76 |
| ▸ | MAOA | P21397 | 3/20 | 0.76 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.76 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9129586 | 1.00 | MAOB (0.76) | MAOBMAOASCN9AGRM5PPARA | |
| SCHEMBL964081 | 0.91 | MAOB (0.63) | MAOBMAOASCN9A | |
| SCHEMBL14329886 | 0.87 | MAOB (0.81) | MAOBMAOASCN9AGRM5PPARA | |
| SCHEMBL2933427 | 0.87 | MAOB (0.81) | MAOBMAOASCN9APPARA | |
| SCHEMBL2933423 | 0.87 | MAOB (0.81) | MAOBMAOASCN9APPARA | |
| SCHEMBL7395880 | 0.87 | MAOB (0.64) | MAOBMAOASCN9AGRM5PPARA | |
| SCHEMBL8935295 | 0.87 | MAOB (0.64) | MAOBMAOASCN9AGRM5PPARA | |
| SCHEMBL8935307 | 0.87 | ALOX5 (0.60) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL69350 | 0.86 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL194169 | 0.86 | MAOB (1.00) | MAOBMAOASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | claimed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | claimed |
| EP-2222290-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-01 | — | — | EP | claimed |
| WO-2009080470-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-07-02 | — | — | WO | claimed |
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | disclosed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | disclosed |
| EP-2222290-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080470-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-07-02 | — | — | WO | disclosed |
| US-5502079-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1996-03-26 | — | — | US | disclosed |
| EP-0400495-B1 | N-phenylalkyl substituted alpha-amino carboxamide derivatives and process for their preparation. | ERBA CARLO SPA (IT) | 1993-11-03 | — | — | EP | disclosed |
| US-5236957-A | Antiepileptic agents | FARMITALIA CARLO ERBA SRL (IT) | 1993-08-17 | — | — | US | disclosed |
| EP-0426816-A1 | N-PHENYLALKYL SUBSTITUTED $g(a)-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-05-15 | — | — | EP | disclosed |
| EP-0400495-A1 | N-phenylalkyl substituted alfa-amino carboxamide derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1990-12-05 | — | — | EP | disclosed |
| WO-1990014334-A1 | N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GABBR1, GABBR2, GABRA5 | MAOB 60/4885MAOA 64/4885SCN9A 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.